Results 151 to 160 of about 491,993 (343)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Kansas energy policy study : final report : government and legal procedures evaluation component of the Kansas energy study [1974]

, 1974
"HUD 701, CPA-KS-07-16-1013."LIST OF TABLES -- LIST OF FIGURES -- CHAPTER ONE INTRODUCTION AND SUMMARY OF BASIC FINDINGS -- CHAPTER TWO FEDERAL ENERGY POLICIES: IMPLICATIONS FOR STATE AND LOCAL GOVERNMENTS -- CHAPTER THREE STATE ENERGY POLICIES: KANSAS ...
Institute for Social and Environmental Studies, the University of Kansas
core  

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

An outdoor recreation plan for central Kansas [1972]

, 1972
"August 1972."INTRODUCTION -- CENTRAL AREA STUDY -- ENVIRONMENTAL CHARACTERISTICS OF CENTRAL KANSAS -- SOCIOECONOMIC CHARACTERISTICS OF CENTRAL KANSAS -- LANDSCAPE SCENIC AND HISTORIC RESOURCES OF CENTRAL KANSAS -- HISTORIC AND SCENIC POTENTIAL OF ...
Kansas Park and Resources Authority
core  

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

An outdoor recreation plan for northwest Kansas [1973]

, 1973
INTRODUCTION -- NORTHWEST AREA STUDY -- ENVIRONMENTAL CHARACTERISTICS OF NORTHWEST KANSAS -- SOCIOECONOMIC CHARACTERISTICS OF NORTHWEST KANSAS -- LANDSCAPE, SCENIC AND HISTORIC RESOURCES OF NORTHWEST KANSAS -- HISTORIC AND SCENIC POTENTIAL OF NORTHWEST ...
Kansas Department of Economic Development, Planning Division
core  

Compensatory Eating Disorder: Disorder, Dimension, or Diagnostic Artefact?

European Eating Disorders Review, EarlyView.
ABSTRACT Compensatory eating disorder (CED) is a newly proposed ‘other specified feeding and eating disorder’ that is characterised by recurrent non‐purging compensatory behaviours, overvaluation of weight and shape, and the absence of objective binge eating, low weight, or recent significant weight loss.
Sonakshi Negi, Angeline R. Bottera, Marianna L. Thomeczek, Elizabeth A. Li, Alexa M. L'Insalata, Robert William Morgan, Sarah Johnson‐Munguia, Kazi Md Farhad Mahmud, Alicia M. Wendler, Mary Oehlert, Kelsie T. Forbush   +10 more
wiley   +1 more source

Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial

Patient Preference and Adherence, 2011
Nia Thompson1, Niaman Nazir1, Lisa Sanderson Cox1,2, Babalola Faseru1,2, Kathy Goggin3, Jasjit S Ahluwalia4, Nicole L Nollen1,21University of Kansas School of Medicine, Department of Preventive Medicine and Public Health, Kansas City, KS, USA ...
Thompson N, Nazir N, Sanderson Cox L, Faseru B, Goggin K, Ahluwalia JS, Nollen NL   +6 more
doaj